Opendata, web and dolomites

AGLYC SIGNED

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

ischemic    morbidity    event    hospital    spanish    diseases    disease    2023    irreversible    pharmaceutical    society    off    mins    la    heart    spin    02    accounting    estimate    nearly    93    founded    progression    medical    market    cvd    pau    23    diagnostics    2015    diagnostic    creu    cardiovascular    vision    65    company    ebitda    deaths    lives    advantages    laboratory    detection    expenses    absence    ir    necrosis    total    events    patients    166    sensitivity    globe    tests    bn    detecting    gt    smei    tissue    onset    15    glycardial    october    represented    model    cagr    31    acute    council    cover    ivd    64    de    santa    first    sales    cardiac    87    projected    49    98    successful    living    demonstrates    reducing    damage    lab    diagnosis    plan    global    business    valued    completion    86       aglyc    medtech    national    prevent    closed    europeans    death    competitive    sublicense    effectiveness    ischemia    device    sant    round    vitro    either    iccc    2017    almost   

Project "AGLYC" data sheet

The following table provides information about the project.

Coordinator
GLYCARDIAL DIAGNOSTICS, SL 

Organization address
address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙727˙139 €
 EC max contribution 1˙908˙997 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCARDIAL DIAGNOSTICS, SL ES (BARCELONA) coordinator 1˙908˙997.00

Map

 Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. In the same year almost 49 m Europeans were living with CVD. Early detection of ischemia is essential to prevent the progression of heart damage and the irreversible tissue damage (necrosis) that can lead to heart failure.

AGLYC is an IVD lab-based test for the early detection of ischemia (15 mins event onset) in the absence of the irreversible necrosis of the tissue. AGLYC demonstrates a 98% sensitivity in detecting the presence of ischemic heart disease. Our main competitive advantages are high sensitivity, early detection of ischemia, and cost effectiveness.

The global in vitro diagnostics (IVD) market was valued at $64.02 bn in 2017 and is projected to reach $87.93 bn by 2023, at a CAGR of 5.2%. The laboratory diagnostic test (lab-based) market represents 86% of the total diagnostic testing market. Specifically, the market for lab tests related to acute cardiac ischemic events represented about $166 m in total sales in 2015. We have estimated a lab-based target market of >70 m patients.

Our main business model will be a sublicense model based on the development of a laboratory-based test that we will develop and then sublicense to either a medical device company (MedTech) or to a pharmaceutical company. With this model and the successful completion of the SMEI phase 2 we estimate an EBITDA of around €23 m.

The company closed a first funding round of €2.4 m on October 2017 to cover nearly 65% of the expenses of the development plan. GlyCardial Diagnostics, S.L. was founded in 2017 as a spin-off of the ICCC- IR-Hospital de la Santa Creu i Sant Pau and the Spanish National Research Council with the focus of developing a novel IVD test for cardiac ischemia. Our vision is to improve the early diagnosis of cardiac ischemic events, reducing the impact of the disease on patients’ lives and society as a whole.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More